ALK-Abelló (ALK-B.CO) Stock Analysis & AI Equity Report
ALK-Abelló (ALK-B.CO) overview
ALK-Abelló (ALK-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, ALK-Abelló reported revenue of DKK 5,537m and operating profit of DKK 1,091m; the year-end share price was 159.10 DKK and market capitalisation was DKK 35,212m. ALK-Abelló is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ALK-Abelló's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About ALK-Abelló
ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company focused on allergy prevention, diagnosis and treatment. It develops and markets allergy immunotherapy products, including tablet, drop and injectable treatments, along with allergen extracts and diagnostics. The company also supplies source materials used in manufacturing allergy products and operates internationally.
Generate the ALK-Abelló report
ALK-Abelló is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ALK-Abelló and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.